logo
After probe report on financial irregularities, all but one clinical trials cancelled at Ahmedabad Hospital

After probe report on financial irregularities, all but one clinical trials cancelled at Ahmedabad Hospital

Indian Express4 days ago
When the investigation into the alleged financial irregularities in clinical trials at an Ahmedabad-based government hospital began, 10 trials were underway at the hospital while seven, for which agreements had been signed, were yet to begin.
With the irregularities coming to light, all the clinical trials that were in their initial phases were shut down, while those that were yet to begin were cancelled, said a senior official of the Ahmedabad Municipal Corporation (AMC).
As of now, only one clinical trial is underway at the Sheth Vadilal Sarabhai General Hospital, Medical Superintendent Dr Parul Shah confirmed with The Indian Express.
Meanwhile, at least four to five doctors accused in the scam have returned the amount deposited in their bank accounts, said Dr Shah.
'We have sent the doctors notices that as per the report, we need to recover the money they received directly for the clinical trials. At least 4-5 doctors have already paid back the amount. The rest are also going to pay us back,' said Dr Shah.
When asked if the hospital would conduct more trials in the coming days, an official said, 'We have decided to not do any clinical trials at the moment till all these irregularities are sorted out.'
As reported by The Indian Express on July 1, a probe panel in Gujarat found financial irregularities in about 65 human clinical trials conducted at the hospital run by the AMC, where 15 doctors allegedly diverted at least Rs 1.87 crore directly to their personal accounts from 2021 — money that should have gone to the hospital first, according to a senior official.
It has now also been learnt that the Drugs Controller General of India (DCGI) has asked the hospital not to conduct any more trials without proper standard operating procedures and permissions.
The clinical trials that the hospital was conducting included those of drugs and formulations from 34 different pharmaceutical companies and clinical research companies (CROs), and were being managed by up to eight Site Management Organisations (SMOs). Of the 65 trials, a total of 48 had been completed, 10 were underway and seven were yet to begin, for which agreements had been signed.
However, according to hospital officials, currently, only one trial is still underway. An official from the AMC Medical Education Trust (AMCMET) said, 'We had stopped most of the clinical trials that were in their initial phases before the investigation began. Only one trial is underway and we will complete that trial in the interest of the patients. No patients have had to suffer due to the financial irregularities.'
Dr Shah said, 'The DCGI team that conducted its investigation here at the hospital said that the clinical trials themselves were conducted in a proper manner. Whatever discrepancies were there, were in the financial aspects. The trials were not compromised.'
The DCGI, when it conducted its three-day investigation in May, asked the hospital to immediately stop the trials, form an ethics committee and get it vetted by the authorities if they wanted to conduct more trials, said sources.
A total of 15 doctors were alleged to have siphoned off Rs 1.87 crore, proceeds from 58 clinical trials, into their personal bank accounts. Only Rs 10.63 lakh had been found to have been deposited in the account of the hospital. An inquiry committee found that a retired Medical Superintendent, an Associate Professor and 12 contractual doctors had been involved in the alleged scam
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

China Retaliates Against EU on Medical-Device Procurement
China Retaliates Against EU on Medical-Device Procurement

Mint

time39 minutes ago

  • Mint

China Retaliates Against EU on Medical-Device Procurement

China will impose some reciprocal curbs on medical-device procurement for companies based in the European Union, adding tensions between the two major trading partners just as Beijing seeks to shore up ties while it fights a trade war with the US. Starting from July 6, EU-based companies will be excluded from Chinese government procurement for certain medical devices if the value is higher than 45 million yuan , according to a statement from the Ministry of Finance on Sunday. Products made by EU-funded companies in China are not impacted by the curbs, the Ministry of Commerce said in a separate statement. China's move came after the EU announced plans to restrict Chinese medical device manufacturers from accessing public procurement contracts worth more than €5 million . The measures will restrict Chinese companies from accessing around 60% of the public spending in this field, or around €150 billion, according to an EU official familiar with the plans. The bloc will also allow no more than 50% of inputs from China for successful bids. Chinese exports of medical devices to the EU have more than doubled between 2015 and 2023, the European Commission said in a statement. In another sign of tension between Europe and Beijing, the Chinese government intended to shorten a two-day summit with EU leaders this month to just a day, Bloomberg reported on Friday. China also announced anti-dumping duties on European brandy on Friday while exempting major cognac makers that agreed to minimum price levels. The action followed the EU's decision in 2024 to levy duties as high as 45% on Chinese-made electric vehicles. European countries have complained that the Chinese government has failed to address overcapacity in sectors including steel, unfair subsidies and market access to its economy. This article was generated from an automated news agency feed without modifications to text.

Small-cap stock under  ₹20 to be in focus on Monday; here's why
Small-cap stock under  ₹20 to be in focus on Monday; here's why

Mint

time39 minutes ago

  • Mint

Small-cap stock under ₹20 to be in focus on Monday; here's why

A small-cap stock under ₹ 20 will likely be in focus on Monday, July 7, following the company's business update. Oriental Trimex, a company that deals in the natural imported marble industry, after market hours on Friday, July 4, shared its business update through an exchange filing, highlighting its improving business efficiency and the prospects of increasing profitability. Oriental Trimex said it became one of the first in the industry to introduce the Smart Cut machine, an ultra-thin wire machine for cutting marble blocks. "The SMART CUT machine employs an ultra-thin wire, just 0.55 millimetres thick, significantly outperforming traditional blades using segments wide enough to 3.5 mm. This innovation reduces waste by about 20 per cent, allowing us to optimise yield and bolster profit margins in an industry where margins typically range from 10 per cent to 30 per cent," said the company. "Moreover, its high automation minimises labour requirements, dramatically enhancing our operational efficiency and securing a first-mover advantage in the market," the company added. Besides, the company also announced the granting of a mining lease for black granite by the Odisha government. "On May 21, 2025, we received an official mining lease from the Odisha government for a quarry of Jer black granite, expanding our product offerings. We are poised to commence quarry operations this quarter and anticipate initiating commercial production shortly thereafter," said Oriental Trimex. "As we drive export initiatives and collaboration forward, we are actively engaging with several Far East and Middle East companies, with discussions with a Vietnam-based partner currently in the final stages," Oriental Trimex said. Oriental Trimex also plans to divest seven acres of land in the Somnathpur Industrial Estate, Balasore, and a small granite unit in the Rairangpur Industrial Area. "This decisive action will streamline our operations, reduce recurring expenses, and enhance liquidity for more focused investments," the company said. Moreover, the company said the growing trend of luxury apartment development in Delhi-NCR has created a vibrant market for its products. The small-cap stock has given impressive returns this year so far, surging 48 per cent. It hit a 52-week high of ₹ 17.63 on June 18 this year and a 52-week low of ₹ 7.82 on August 8 last year. Read all market-related news here Disclaimer: This story is for educational purposes only. The views and recommendations expressed are those of individual analysts or broking firms, not Mint. We advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and circumstances may vary.

ChatGPT Plus And Gemini AI Pro Cost The Same In India: Which One Should You Buy?
ChatGPT Plus And Gemini AI Pro Cost The Same In India: Which One Should You Buy?

News18

time40 minutes ago

  • News18

ChatGPT Plus And Gemini AI Pro Cost The Same In India: Which One Should You Buy?

Last Updated: ChatGPT and Gemini premium plans cost over Rs 1,900 per month in India but how do they compare and which one is better? ChatGPT Plus and Gemini AI Pro are two paid versions of the popular AI chatbots from OpenAI and Google, respectively. The companies have invested billions into their AI products and now looking to recoup some of that money from its consumers. And the best way to do that is to offer a package of the AI chatbots that not only unlocks the latest AI models but also bundles them with a slew of services which makes it attractive for the money people are being asked to pay. ChatGPT Plus costs Rs 1,900 per month in India, while the Gemini AI Pro version comes for Rs 1,950 per month, which makes them similar in terms of the price range. But do they offer the same set of features or does OpenAI have more in the bank than a giant like Google? We've decided to do this comparison and help you out with the details. ChatGPT Plus vs Gemini AI Pro Price In India ChatGPT Plus is priced at Rs 1,900 which has to be paid every month. Google is charging Rs 1,950 per month for the Gemini AI Pro plan in India. Earlier it used to be called the Gemini Advanced plan. Besides these you also get support for voice conversations, image generation (using DALL-E), File uploads and analysis, Deep Research tools (where available) and Custom GPT creation. People have been appealed by these features because their other options were limited. But Google Gemini AI Pro takes the Plus model head on and delivers a more compelling set of benefits. Here's what you get from Google: And recently, Google announced that the Veo 3 AI model let you generate 10 videos with native audio support if you take the Gemini AI Pro plan. Granted, both these AI chatbot plans have certain limits but that is expected when you pay under Rs 2,000 per month to access the latest and powerful AI models from these companies. And that's why they have another premium tier plan called the ChatGPT Pro and the Gemini Ultra that gives you all the Plus/Pro features but opens up the AI models to a whole new playground for the users. First Published:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store